A
Acesion Pharma
Develops drugs for the treatment of atrial fibrillation
About Acesion Pharma
Acesion Pharma is a Danish clinical-stage biotechnology company founded in 2011, specializing in the development of novel treatments for atrial fibrillation (AF), the most prevalent cardiac arrhythmia.
The company's core focus is on the inhibition of SK ion channels, a distinct approach to managing AF. Its lead drug candidate, AP30663, is designed for the acute cardioversion of AF, aiming to restore a normal heart rhythm. Acesion has demonstrated clinical proof-of-concept for AP30663 and is also advancing a second candidate, AP31969, for the prevention of AF recurrence.
The company's business model revolves around the research and development of these drug candidates, with the goal of bringing them to market. The successful closure of an oversubscribed €45 million Series B financing round indicates a strong level of investor confidence in its therapeutic pipeline and strategy. Acesion Pharma operates in the pharmaceutical and biotechnology market, targeting a significant patient population affected by atrial fibrillation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Copenhagen, Denmark
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 78.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2023 | $50M | $198M | Novo Holdings · Global BioAccess Fund · Canaan · Alpha Wave Global | ↗ |
| SERIES AOther financing | Nov 2016 | $10M | $40M | Novo Holdings · Wellcome Trust | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Acesion Pharma is 650 monthly website visits, down 72.9% over the last three months. Acesion Pharma's team grew 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Wellcome Trust
Broadview Ventures
Novo Holdings
Novo Seeds
Canaan
Alpha Wave Global
Global BioAccess Fund
Other known investors1 additional known investor
University of Copenhagen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acesion Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acesion Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.